Glofitamab
Based on 1 publication(s) in Google Scholar
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.12%
- CAS 番号: 2229047-91-8
- 分子量:194 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Glofitamab
More
生物活性
IgG1-kappa/lambda with domain crossover, trivalent
Human
CD3E & MS4A1
Glofitamab (0.1 µg/mL, 48 h) stimulates the expression of 4-1BB (CD137) on CD8+ tumor-infiltrating lymphocyte (TILs) in the lymphoma tumor microenvironment (TMEs) and augmented diffuse large B cell lymphoma (DLBCL) cell death combined with either FAP-IL2v (HY-P99902) or FAP-4-1BBL[4].
Glofitamab (0.2-200 ng/mL, 16 h)-mediated DLBCL cell killing requires the formation of stable T effector cell-tumor cell synapses[5].
Glofitamab has no effect on the transient reduction in T-lymphocyte subsets, NK cells and monocytes by Obinutuzumab (HY-P9910) pretreatment (Gpt)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Glofitamab (0.5 mg/kg, i.v., a single dose) induces early and lasting T cell engagement and activity in mice[5].
Pharmacokinetic parameters of Glofitamab (i.v., a single dose) in cynomolgus monkeys with or without Obinutuzumab (Gpt: 50 mg/kg) (MeSt: Mechanistic Study; MTD: Maximum Tolerated Dose)[3]
| Study | Gpt | Dose (μg/kg) | CL(mL/day/kg) | Vc(mL/kg) | T1/2 (days) | Cmax (μg/mL) | AUClast/dose(h·μg/mL/μg/kg) |
| MTD | No | 0.3 | nd | nd | nd | 0.00374/0.00663 | nd |
| MTD | No | 1 | nd | 45.6/nd | nd | 0.0188/nd | 0.0162/nd |
| MTD | No | 3 | 864/920 | 35.8/31.9 | 0.218/0.180 | 0.0704/0.0798 | 0.0218/0.0234 |
| MTD | No | 10 | 735/656 | 26.7/24.6 | 0.143/0.159 | 0.318/0.354 | 0.0290/0.0339 |
| MTD | No | 30 | 600/653 | 27.9/36.1 | 0.173/0.151 | 0.958/0.759 | 0.0397/0.0335 |
| MTD | No | 100 | 190/290 | 34.9/41.6 | 0.203/0.113 | 2.74/2.29 | 0.126/0.0826 |
| MeSt | No | 100 | 384±106 | 43.2±7.26 | 0.314±0.158 | 2.22±0.384 | 0.0679±0.0246 |
| MeSt | Yes | 100 | 81.7±18.3 | 41.1±5.59 | 2.82±0.959 | 2.56±0.320 | 0.308±0.0773 |